Protocol Summaries: GSK1572932
| GSK Study ID |
Phase | Title | Status |
|---|---|---|---|
| 107240 | Phase 1 | Cancer immunotherapeutic GSK1572932A as adjuvant therapy for patients with MAGE-A3-positive Non-Small Cell Lung cancer | Recruiting |
| 109493 | Phase 3 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3 positive Non-Small Cell Lung Cancer | Recruiting |